Helmut Sinzinger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Helmut Sinzinger has a total of 202 co-authors. Here are the top co-authors by number of shared publications:
H Kritz
24 shared publicationsP Fitscha
24 shared publicationsJ Kaliman
14 shared publicationsA Oguogho
Department of Nuclear Medicine, University of Vienna, Austria
10 shared publications- Christian Pirich
Division of Molecular Imaging & Theranostics, Department of Nuclear Medicine, University Hospital, Paracelsus Medical University, Salzburg, Austria
10 shared publications M Rodrigues
Department of Nuclear Medicine, University Hospital, Vienna, Austria
9 shared publications
Latest Publications
- 1 December 2006
- Vol. 50 (4) , 334-43
Modification of low-density lipoprotein during radiolabeling with 99mTc using three labeling methods.
The mechanisms of native low-density lipoprotein (LDL) uptake by monocytes and macrophages via the specific cholesterol down-regulated LDL-receptor differs form the mechanism responsible for the unregulated scavenging of the modified, for example, oxidized LDL, by the atherosclerotic plaques and foam cells. For this reason, we investigated if the 99mTc-labeled LDL stands for the native or modified molecule. The influence of the LDL sampling methods, isolation, preparation and radiolabeling of lipoproteins on structure modification and the subsequent imaging behavior has as yet not been addressed in detail. Herein we present data on the effects of 99mTc labeling on some oxidation relevant parameters of LDL, such as the lag-time, thiobarbituric acid reactive substances (TBARS), relative electrophoretic mobility (REM), baseline dienes (BD), lipid peroxides (POX), free amino-groups (NH2-groups) and free sulphydryl-groups (SH-groups). Three methods of 99mTc labeling were compared: dithionite method (1), borohydride method (2) and ascorbic acid method (3). Data for oxidation parameters are expressed as a percent of freshly isolated native LDL (% native LDL) or as a percent of LDL treated with the labeling buffers and reagents, but in absence of the radioisotope (% control LDL). The levels of BD were most influenced by methods 2 and 3, and remained almost unchanged when the method 1 was used. The lag-time of 99mTc-LDL produced by method 2 doubled but it was decreased by 23% when the method 3 was employed. No change in the lag-time compared to the native LDL was observed with the method 1. The TBARS levels were 3-5 fold higher than in native LDL when methods 1 and 2 were used, but 33% lower in products made by the method 3. The number of thiol groups increased 3 fold in method 1, was only slightly elevated in method 3, but reduced in method 2 compared to native LDL. NH2-groups were increased with all three labeling procedures, but this increase was not considered significant. REM was altered only in products obtained by methods 1 (1.5x increase) and by method 2 (1.25x increase). No fragmentation of Apo B using sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) electrophoresis was observed by 99mTc-LDL produced in any of the The increase of lipid peroxide generation was observed only when the method 2 was used. Of the three tested methods, we found all of them to render LDL oxidatively modified to some extent. Therefore, it appears that the native-LDL imaging with 99mTc-labeled LDL is impossible. Only the ascorbic acid method 3 appears to offer some protection and exerts antioxidant effects.
- 1 December 2006
- Vol. 50 (4) , 334-43
Modification of low-density lipoprotein during radiolabeling with 99mTc using three labeling methods.
The mechanisms of native low-density lipoprotein (LDL) uptake by monocytes and macrophages via the specific cholesterol down-regulated LDL-receptor differs form the mechanism responsible for the unregulated scavenging of the modified, for example, oxidized LDL, by the atherosclerotic plaques and foam cells. For this reason, we investigated if the 99mTc-labeled LDL stands for the native or modified molecule. The influence of the LDL sampling methods, isolation, preparation and radiolabeling of lipoproteins on structure modification and the subsequent imaging behavior has as yet not been addressed in detail. Herein we present data on the effects of 99mTc labeling on some oxidation relevant parameters of LDL, such as the lag-time, thiobarbituric acid reactive substances (TBARS), relative electrophoretic mobility (REM), baseline dienes (BD), lipid peroxides (POX), free amino-groups (NH2-groups) and free sulphydryl-groups (SH-groups). Three methods of 99mTc labeling were compared: dithionite method (1), borohydride method (2) and ascorbic acid method (3). Data for oxidation parameters are expressed as a percent of freshly isolated native LDL (% native LDL) or as a percent of LDL treated with the labeling buffers and reagents, but in absence of the radioisotope (% control LDL). The levels of BD were most influenced by methods 2 and 3, and remained almost unchanged when the method 1 was used. The lag-time of 99mTc-LDL produced by method 2 doubled but it was decreased by 23% when the method 3 was employed. No change in the lag-time compared to the native LDL was observed with the method 1. The TBARS levels were 3-5 fold higher than in native LDL when methods 1 and 2 were used, but 33% lower in products made by the method 3. The number of thiol groups increased 3 fold in method 1, was only slightly elevated in method 3, but reduced in method 2 compared to native LDL. NH2-groups were increased with all three labeling procedures, but this increase was not considered significant. REM was altered only in products obtained by methods 1 (1.5x increase) and by method 2 (1.25x increase). No fragmentation of Apo B using sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) electrophoresis was observed by 99mTc-LDL produced in any of the The increase of lipid peroxide generation was observed only when the method 2 was used. Of the three tested methods, we found all of them to render LDL oxidatively modified to some extent. Therefore, it appears that the native-LDL imaging with 99mTc-labeled LDL is impossible. Only the ascorbic acid method 3 appears to offer some protection and exerts antioxidant effects.
- 1 September 2004
- Vol. 48 (3) , 207-10
Should lidocaine be avoided for local anesthesia in radiation synovectomy?
Leakage is of major concern when performing radiation synovectomy. Although post-treatment immobilization was provided, extra-articular leakage of radioactivity has occasionally been observed in patients receiving local anesthesia in the course of radiation synovectomy. This study was performed to uncover any unfavourable effect of lidocaine on stability of (166)Ho-FHMA (ferrum hydroxide macroaggregate). The radiopharmaceutical was investigated in bovine serum albumin (BSA) solutions (5, 10 mg/ml) at pH 6, 7 and 8. Furthermore, the tracer was incubated for 0, 2, 24, 48 and 120 hours in synovial fluid. In both series the influence of lidocaine-HCl 2% (500, 1000 microl) has been evaluated. In BSA test solutions, amount of lidocaine added [df(2), F=7.82, p-level: 0.00] and pH [df(2), F=7.82, p-level: 0.00] significantly influenced in vitro stability of (166)Ho labeled FHMA (n=72). This finding was confirmed in synovial fluid [df(2), F=3.82, p-level: 0.03] (n=60). In an experimental design mimicking normal and inflammatory conditions in the joint, addition of a few milliliters of lidocaine-HCl followed by a shift towards lower pH-values in synovial fluid may endanger stability of the carrier-tracer complex (166)Ho-FHMA and thereby enhance extra-articular leakage.
- 1 September 2004
- Vol. 48 (3) , 207-10
Should lidocaine be avoided for local anesthesia in radiation synovectomy?
Leakage is of major concern when performing radiation synovectomy. Although post-treatment immobilization was provided, extra-articular leakage of radioactivity has occasionally been observed in patients receiving local anesthesia in the course of radiation synovectomy. This study was performed to uncover any unfavourable effect of lidocaine on stability of (166)Ho-FHMA (ferrum hydroxide macroaggregate). The radiopharmaceutical was investigated in bovine serum albumin (BSA) solutions (5, 10 mg/ml) at pH 6, 7 and 8. Furthermore, the tracer was incubated for 0, 2, 24, 48 and 120 hours in synovial fluid. In both series the influence of lidocaine-HCl 2% (500, 1000 microl) has been evaluated. In BSA test solutions, amount of lidocaine added [df(2), F=7.82, p-level: 0.00] and pH [df(2), F=7.82, p-level: 0.00] significantly influenced in vitro stability of (166)Ho labeled FHMA (n=72). This finding was confirmed in synovial fluid [df(2), F=3.82, p-level: 0.03] (n=60). In an experimental design mimicking normal and inflammatory conditions in the joint, addition of a few milliliters of lidocaine-HCl followed by a shift towards lower pH-values in synovial fluid may endanger stability of the carrier-tracer complex (166)Ho-FHMA and thereby enhance extra-articular leakage.
- 1 May 2004
- Published by Elsevier in Revista Española de Medicina Nuclear
- Vol. 23 (3) , 183-188
(Iso) Prostaglandins in saliva indicate oxidation injury after radioiodine therapy
- 1 May 2004
- Published by Elsevier in Revista Española de Medicina Nuclear
- Vol. 23 (3) , 183-188
(Iso) Prostaglandins in saliva indicate oxidation injury after radioiodine therapy
- 1 January 2003
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 42 (06) , 251-254
Radiation doses deriving from patients treated with 166Ho-ferric hydroxide
Aim: To estimate radiation doses deriving from patients treated with 166Ho ferric hydroxide. Methods: For radiation synoviorthesis about 900 ± 100 MBq 166Ho ferric hydroxide was injected into the knee joint of 16 patients. To estimate the radiation exposure of persons in the neighbourhood of the patients measurements of the dose rates were performed at 0.5 m, 1 m and 2 m distance of the treated joint 10 min after tracer injection. Measurements were carried out with and without radiation protection devices of the syringe. Results: The initial values of the dose rate were 11.9 μSv/h at 0.5 m, 3.5 μSv/h at 1 m and 1 μSv/h at 2 m distance, respectively. The whole body doses were 2.9 μSv for the physician and 4.6 μSv for the technologist. The finger doses for the technologist and the physician were ranging from 65 to 111 μSv. After discharge at home other persons might receive 118 μSv. Conclusion: Our results, under very strict assumptions, clearly demonstrate that the calculated radiation exposure to medical and non medical personnel is well below the maximum annual dose limit. The use of any additional radiation protection device as syringe shielding does not significantly lower radiation exposure. Ziel: Ermittlung der Strahlenbelastung für medizinisches Personal, Begleitpersonen und Familienangehörige durch Patienten, die sich einer Radiosynoviorthese mit 166Ho unterziehen. Methode: 10 min nach Applikation von 900 ± 100 MBq 166Ho Eisenhydroxid in das Kniegelenk von 16 Patienten wurden in 0,5 m, 1 m und 2 m Entfernung die Dosisleistungen mit einem geeichten Strahlenmessgerät gemessen. Zur Evaluierung der Behandlungsmethode mit minimaler Strahlenbelastung für das medizinische Personal wurden sowohl Applikationen mit spezieller Abschirmung für die Spritzen als auch Applikationen mit unabgeschirmten Spritzen durchgeführt. Aus den Dosiswerten, die aus den gemessenen Ortsdosisleistungen berechnet wurden, und den gemessenen Dosiswerten der Fingerringdosimeter wurde die Strahlenbelastung von Personen in der Umgebung der Patienten abgeschätzt. Ergebnisse: Die Dosisleistungen in der Nähe der Patienten betrugen kurz nach der Applikation im Mittel 11,9 μSv/h in 0,5 m Entfernung, 3,5 μSv/h in 1 m Entfernung und 1 μSv/h in 2 m Entfernung. Die Mittelwerte der gemessenen Fingerdosen lagen im Be-reich von 65-111 μSv für das medizinische Personal pro Behandlung. Die durchschnittliche berechnete Personendosis für den Arzt betrug 2,9 μSv und 4,6 μSv für das medizinisch technische Personal. Personen, die sich in der Nähe des Patienten aufhalten, können eine Dosis von 118 μSv erhalten. Schlussfolgerung: Betrachtet man die berechneten Dosiswerte, wobei von äußerst restriktiven Annahmen ausgegangen wurde, so liegen diese Werte weit unter den höchstzulässigen Grenzwerten. Man kann davon ausgehen, dass die tatsächlichen Dosen in der Praxis deutlich unter den berechneten Dosiswerten liegen. Die Ergebnisse zeigen, dass bei der vorliegenden Behandlungsmethode aus der Sicht des Strahlenschutzes keine zusätzlichen Abschirmungen oder besonderen Vorsichtsmaßnahmen, welche über die üblichen Sicherheitsvorkehrungen in einem nuklearmedizinischen Betrieb hinausgehen, notwendig sind.
- 1 January 2003
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 42 (06) , 251-254
Radiation doses deriving from patients treated with 166Ho-ferric hydroxide
Aim: To estimate radiation doses deriving from patients treated with 166Ho ferric hydroxide. Methods: For radiation synoviorthesis about 900 ± 100 MBq 166Ho ferric hydroxide was injected into the knee joint of 16 patients. To estimate the radiation exposure of persons in the neighbourhood of the patients measurements of the dose rates were performed at 0.5 m, 1 m and 2 m distance of the treated joint 10 min after tracer injection. Measurements were carried out with and without radiation protection devices of the syringe. Results: The initial values of the dose rate were 11.9 μSv/h at 0.5 m, 3.5 μSv/h at 1 m and 1 μSv/h at 2 m distance, respectively. The whole body doses were 2.9 μSv for the physician and 4.6 μSv for the technologist. The finger doses for the technologist and the physician were ranging from 65 to 111 μSv. After discharge at home other persons might receive 118 μSv. Conclusion: Our results, under very strict assumptions, clearly demonstrate that the calculated radiation exposure to medical and non medical personnel is well below the maximum annual dose limit. The use of any additional radiation protection device as syringe shielding does not significantly lower radiation exposure. Ziel: Ermittlung der Strahlenbelastung für medizinisches Personal, Begleitpersonen und Familienangehörige durch Patienten, die sich einer Radiosynoviorthese mit 166Ho unterziehen. Methode: 10 min nach Applikation von 900 ± 100 MBq 166Ho Eisenhydroxid in das Kniegelenk von 16 Patienten wurden in 0,5 m, 1 m und 2 m Entfernung die Dosisleistungen mit einem geeichten Strahlenmessgerät gemessen. Zur Evaluierung der Behandlungsmethode mit minimaler Strahlenbelastung für das medizinische Personal wurden sowohl Applikationen mit spezieller Abschirmung für die Spritzen als auch Applikationen mit unabgeschirmten Spritzen durchgeführt. Aus den Dosiswerten, die aus den gemessenen Ortsdosisleistungen berechnet wurden, und den gemessenen Dosiswerten der Fingerringdosimeter wurde die Strahlenbelastung von Personen in der Umgebung der Patienten abgeschätzt. Ergebnisse: Die Dosisleistungen in der Nähe der Patienten betrugen kurz nach der Applikation im Mittel 11,9 μSv/h in 0,5 m Entfernung, 3,5 μSv/h in 1 m Entfernung und 1 μSv/h in 2 m Entfernung. Die Mittelwerte der gemessenen Fingerdosen lagen im Be-reich von 65-111 μSv für das medizinische Personal pro Behandlung. Die durchschnittliche berechnete Personendosis für den Arzt betrug 2,9 μSv und 4,6 μSv für das medizinisch technische Personal. Personen, die sich in der Nähe des Patienten aufhalten, können eine Dosis von 118 μSv erhalten. Schlussfolgerung: Betrachtet man die berechneten Dosiswerte, wobei von äußerst restriktiven Annahmen ausgegangen wurde, so liegen diese Werte weit unter den höchstzulässigen Grenzwerten. Man kann davon ausgehen, dass die tatsächlichen Dosen in der Praxis deutlich unter den berechneten Dosiswerten liegen. Die Ergebnisse zeigen, dass bei der vorliegenden Behandlungsmethode aus der Sicht des Strahlenschutzes keine zusätzlichen Abschirmungen oder besonderen Vorsichtsmaßnahmen, welche über die üblichen Sicherheitsvorkehrungen in einem nuklearmedizinischen Betrieb hinausgehen, notwendig sind.
- 1 November 2002
- Published by Elsevier in Prostaglandins, Leukotrienes and Essential Fatty Acids
- Vol. 67 (5) , 309-310
Comments on “Relationship between thromboxane/prostacyclin ratio and diabetic vascular complications”
- 1 November 2002
- Published by Elsevier in Prostaglandins, Leukotrienes and Essential Fatty Acids
- Vol. 67 (5) , 309-310
Comments on “Relationship between thromboxane/prostacyclin ratio and diabetic vascular complications”
- 1 August 2002
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 40 (2) , 163-171
Muscular Side Effects of Statins
Lipid lowering has been shown to be effective in preventing primary and recurrent cardiovascular events and to save life. Statins almost exclusively used for this purpose meanwhile became one of the most widely prescribed families of drugs world-wide. Myopathies – mainly not well characterized – are the major group of side effects. We here review different types of clinical appearances, localizations, symptoms and the biochemical background. The data indicate that severe muscular side effects are rare. Patients and their doctors, however, easily overlook mild ones. Myopathic symptoms without any known biochemical correlate are not rare. No general guideline exists about exact diagnosis and differential diagnosis. Strict adherence to the measures of life-style change and performance of regular exercise can even further enhance significantly these side effects. Much more research should be directed onto the pathophysiological (genetic?) background to finally evaluate possible therapeutic consequences rather than simply to withdraw or change the respective statin.
- 1 August 2002
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 40 (2) , 163-171
Muscular Side Effects of Statins
Lipid lowering has been shown to be effective in preventing primary and recurrent cardiovascular events and to save life. Statins almost exclusively used for this purpose meanwhile became one of the most widely prescribed families of drugs world-wide. Myopathies – mainly not well characterized – are the major group of side effects. We here review different types of clinical appearances, localizations, symptoms and the biochemical background. The data indicate that severe muscular side effects are rare. Patients and their doctors, however, easily overlook mild ones. Myopathic symptoms without any known biochemical correlate are not rare. No general guideline exists about exact diagnosis and differential diagnosis. Strict adherence to the measures of life-style change and performance of regular exercise can even further enhance significantly these side effects. Much more research should be directed onto the pathophysiological (genetic?) background to finally evaluate possible therapeutic consequences rather than simply to withdraw or change the respective statin.
- 1 May 2002
- Published by Elsevier in Thrombosis Research
- Vol. 106 (4-5) , 187-190
Antiplatelet activity of semotiadil fumarate
- 1 May 2002
- Published by Elsevier in Thrombosis Research
- Vol. 106 (4-5) , 187-190
Antiplatelet activity of semotiadil fumarate
- 1 January 2002
- Published by Springer Nature in Drug Safety
- Vol. 25 (12) , 877-883
Oxidation Injury in Patients Receiving HMG-CoA Reductase Inhibitors
Background: Myopathy in its severe forms including rhabdomyolysis is a very rare adverse effect occurring during monotherapy with the HMG-CoA reductase inhibitors (‘statins’) and is associated with pronounced signs of oxidation injury. This has been found at a local (muscle) as well as at a systemic level (blood). Several lines of evidence indicate that even mild forms of myopathy during statin treatment may be associated with in vivo oxidation injury. In contrast, statin therapy has been shown to be associated with a decrease in oxidation injury. Objective: The aim of this study was to investigate whether patients with heterozygous familial hypercholesterolaemia who did not exhibit any symptoms or abnormalities in safety parameters during 6 months of treatment with various statins (atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin) did exhibit a change in oxidation injury as assessed by the isoprostane levels. Methods: Blood (plasma and serum) as well as urine was tested before and 1, 3 and 6 months after starting statin therapy. Results: Out of 111 treated patients (63 males, 48 females; aged 19 to 58 years) who did not experience any adverse effects during statin treatment, 11 (seven males, four females; aged 24 to 51 years) showed a pronounced increase in 8-epi-prostaglandin (PG) F2α in all the compartments examined. In the remaining 100 patients (56 males, 44 females; aged 19 to 58 years) there was either no change in or even an apparent decrease in 8-epi-PGF2α. This increase was monitored with all the statins administered. If elevated, the increase in 8-epi-PGF2α remained without change throughout the entire follow-up period. No sex difference or differential response between smokers and nonsmokers was observed. Discussion: These findings indicate that in the absence of other clinically observable adverse effects, in some of the patients, for an as yet unknown reason, statin therapy may be associated with increased oxidation injury. The fact that changing to another statin is apparently not necessarily associated with an identical response raises the question of a specific predisposition for certain compounds in a given patient. These data add a further piece of evidence that mild adverse effects of statins that are difficult to assess might be much more prevalent than widely considered. The clinical relevance and consequence of these findings still remains to be assessed.
- 1 January 2002
- Published by Springer Nature in Drug Safety
- Vol. 25 (12) , 877-883
Oxidation Injury in Patients Receiving HMG-CoA Reductase Inhibitors
Background: Myopathy in its severe forms including rhabdomyolysis is a very rare adverse effect occurring during monotherapy with the HMG-CoA reductase inhibitors (‘statins’) and is associated with pronounced signs of oxidation injury. This has been found at a local (muscle) as well as at a systemic level (blood). Several lines of evidence indicate that even mild forms of myopathy during statin treatment may be associated with in vivo oxidation injury. In contrast, statin therapy has been shown to be associated with a decrease in oxidation injury. Objective: The aim of this study was to investigate whether patients with heterozygous familial hypercholesterolaemia who did not exhibit any symptoms or abnormalities in safety parameters during 6 months of treatment with various statins (atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin) did exhibit a change in oxidation injury as assessed by the isoprostane levels. Methods: Blood (plasma and serum) as well as urine was tested before and 1, 3 and 6 months after starting statin therapy. Results: Out of 111 treated patients (63 males, 48 females; aged 19 to 58 years) who did not experience any adverse effects during statin treatment, 11 (seven males, four females; aged 24 to 51 years) showed a pronounced increase in 8-epi-prostaglandin (PG) F2α in all the compartments examined. In the remaining 100 patients (56 males, 44 females; aged 19 to 58 years) there was either no change in or even an apparent decrease in 8-epi-PGF2α. This increase was monitored with all the statins administered. If elevated, the increase in 8-epi-PGF2α remained without change throughout the entire follow-up period. No sex difference or differential response between smokers and nonsmokers was observed. Discussion: These findings indicate that in the absence of other clinically observable adverse effects, in some of the patients, for an as yet unknown reason, statin therapy may be associated with increased oxidation injury. The fact that changing to another statin is apparently not necessarily associated with an identical response raises the question of a specific predisposition for certain compounds in a given patient. These data add a further piece of evidence that mild adverse effects of statins that are difficult to assess might be much more prevalent than widely considered. The clinical relevance and consequence of these findings still remains to be assessed.
- 1 January 2002
- Published by Taylor & Francis in Journal of Receptors and Signal Transduction
- Vol. 22 (1-4) , 459-470
BINDING OF [99mTc]CHONDROITIN SULFATE TO SCAVENGER RECEPTORS ON HUMAN CHONDROCYTES AS COMPARED TO BINDING OF OXIDIZED [125I]LDL ON HUMAN MACROPHAGES
Chondroitin sulfate (CS) used for treatment of osteoarthritis exerts distinct effects on human articular chondrocytes in vitro. We performed a binding analysis with 99mTc-labeled CS (Condrosulf, a commercial CS preparation containing calcium stearate) and cultured human chondrocytes in order to evaluate the presence of specific receptors. Saturation binding at 37 degrees C for 2 h revealed the presence of high-affinity binding sites for CS with a Kd of 2.3 x 10(-9) mol/L and a Bmax of 5.0 x 10(8). Extensive dialysis of Chondrosulf led to a decrease of the binding affinity by 52.5 +/- 19.5% and of the number of CS binding sites/cell by 62.0 +/- 14.0%, demonstrating that the additive present in the Condrosulf preparation enhances CS binding. The nature of the binding site is not yet known but evidence exists in the literature that the scavenger receptor CD36, thoroughly investigated on macrophages, is also found on chondrocytes and might be involved in CS binding. Therefore, we undertook a comparative binding study with human monocytes and labelled LDL and oxidized LDL, the latter being a postulated atherogenic agent in atherosclerosis. For [125I]-LDL binding we found a Kd of 0.45 x 10(-8) mol/L and a Bmax of 0.14 x 10(6) on quiescent monocytes and for [125I]-(ox)LDL binding a Kd of 1.8 x 10(-8) mol/L and a Bmax of 1.3 x 10(6) using LPS-activated monocytes. These data are comparable to the binding affinity found for lipoprotein-proteoglycan-complexes and hence are an indication but not a proof that CD36 is involved in CS binding to human chondrocytes.
- 1 January 2002
- Published by Taylor & Francis in Journal of Receptors and Signal Transduction
- Vol. 22 (1-4) , 459-470
BINDING OF [99mTc]CHONDROITIN SULFATE TO SCAVENGER RECEPTORS ON HUMAN CHONDROCYTES AS COMPARED TO BINDING OF OXIDIZED [125I]LDL ON HUMAN MACROPHAGES
Chondroitin sulfate (CS) used for treatment of osteoarthritis exerts distinct effects on human articular chondrocytes in vitro. We performed a binding analysis with 99mTc-labeled CS (Condrosulf, a commercial CS preparation containing calcium stearate) and cultured human chondrocytes in order to evaluate the presence of specific receptors. Saturation binding at 37 degrees C for 2 h revealed the presence of high-affinity binding sites for CS with a Kd of 2.3 x 10(-9) mol/L and a Bmax of 5.0 x 10(8). Extensive dialysis of Chondrosulf led to a decrease of the binding affinity by 52.5 +/- 19.5% and of the number of CS binding sites/cell by 62.0 +/- 14.0%, demonstrating that the additive present in the Condrosulf preparation enhances CS binding. The nature of the binding site is not yet known but evidence exists in the literature that the scavenger receptor CD36, thoroughly investigated on macrophages, is also found on chondrocytes and might be involved in CS binding. Therefore, we undertook a comparative binding study with human monocytes and labelled LDL and oxidized LDL, the latter being a postulated atherogenic agent in atherosclerosis. For [125I]-LDL binding we found a Kd of 0.45 x 10(-8) mol/L and a Bmax of 0.14 x 10(6) on quiescent monocytes and for [125I]-(ox)LDL binding a Kd of 1.8 x 10(-8) mol/L and a Bmax of 1.3 x 10(6) using LPS-activated monocytes. These data are comparable to the binding affinity found for lipoprotein-proteoglycan-complexes and hence are an indication but not a proof that CD36 is involved in CS binding to human chondrocytes.
- 20 August 2001
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 26 (4) , 303-310
Isoprostane 8-epi-PGF2alpha is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Co-enzyme-A-reductase inhibitor therapy
Background: Muscle pains with or without CK‐elevation are among the most frequently observed side‐effects in patients with hyperlipoproteinemia on various statins. The pathophysiological background,...
- 20 August 2001
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 26 (4) , 303-310
Isoprostane 8-epi-PGF2alpha is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Co-enzyme-A-reductase inhibitor therapy
Background: Muscle pains with or without CK‐elevation are among the most frequently observed side‐effects in patients with hyperlipoproteinemia on various statins. The pathophysiological background,...